Pharmafile Logo
Pharmafocus logo
Advanced Search

Phage Pharma appoints David Jackson

pharmafile | July 27, 2010 | Appointment | Manufacturing and Production |  Phage, appointment, manufacturing and production 

US clinical-stage development and manufacturing company Phage Pharmaceuticals has appointed David Jackson VP of operations planning.

He will be responsible for oversight of the company’s cGMP-certified therapeutic protein manufacturing facility in San Diego and reports to chief executive Robert Beckman.

Prior to joining Phage, David was VP of process development and manufacturing at VaxInnate Corporation, and has previously served as VP of US operations and later VP of global biologics manufacturing at Lonza Biologics.

Advertisement

His previous roles also include VP of manufacturing at BioReliance and VP of manufacturing and pharmaceutical support at EntreMed.

Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products

Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026